Physician profile
Stephen Stephenson
NPI 1376561613
$19,865.62
in general payments reported to CMS, 2019-2025
46 companies · $3,570 in 2025
The $3,570 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,296 · 2020: $1,956 · 2021: $3,167 · 2022: $2,954 · 2023: $2,483 · 2024: $3,439 · 2025: $3,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,434 · Education: $58.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,434.09 |
| Education | $58.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,630.72 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $4,137.36 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $1,741.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,435.30 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,074.15 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $785.48 | 2019-2024 | Linzess |
| Alnylam Pharmaceuticals INC. | $606.41 | 2020-2025 | Givlaari |
| Pfizer INC. | $514.37 | 2019-2025 | |
| Redhill Biopharma INC. | $452.18 | 2020-2023 | Talicia, Movantik |
| Vivus LLC | $366.83 | 2021-2025 | Qsymia, Pancreaze |
| Qol Medical, LLC | $347.18 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $285.46 | 2019-2023 | Ocaliva |
| Daiichi Sankyo INC. | $283.23 | 2019-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $282.39 | 2025 | Zenpep |
| Genzyme Corporation | $279.98 | 2022-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.